. Development of SM in mice transplanted with TRKB-and BDNF-modified hematopoietic stem/progenitor cells. (A-F) Representative histopathology (hematoxylin and eosin) and cytology (May-Grünwald-Giemsa) from 2 animals (A-E: mouse 1007, F: mouse 746). The World Health Organization criteria for human SM were fulfilled in diseased animals. 6, 7 Multifocal, dense infiltrates of mast cells ($15 mast cells in aggregates) were observed in different organs. and transgene negative populations (K, negative control for panels H-K shown as inset). These demonstrated that abnormal mast cells were derived from gene-modified cells. It is interesting to note that in SM mice, both autocrine and paracrine loops may have contributed to mastocytosis ( Figure 1G ), whereas we observed a clear selection for both lymphoid leukemia (supplemental Figure 4 ) and myeloid leukemia transformation by autocrine activation of TRKB. 4 Activation of TRKB in hematopoietic stem/progenitor cells induced 2 different phenotypes in vivo, ie, SM and lymphoblastic leukemia. This might be due to different cell populations targeted, 10 although other factors might also be involved.
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To investigate the role of TRKB signaling in leukemogenesis, 37 C57BL/6J mice were transplanted with retrovirally gene-modified primary hematopoietic stem/progenitor cells (TRKB/BDNF 5 17, TRKB 5 8, BDNF 5 5, tCD34 5 7) in 3 independent experiments (some data from the first experiment were recently published 4 ). The experiments were terminated after an observation time of up to 454 days (mean 354 days). Interestingly, lymphoblastic leukemia was diagnosed in 5 animals (supplemental Data; available on the Blood Web site), whereas the other 12 animals with coexpression of TRKB/BDNF unexpectedly developed SM, affecting mainly spleen, liver, and bone marrow (see figure panels A-F) with multifocal compact mast cell infiltrates. Mast cells demonstrated mainly features of mature hypergranular mast cells (Figure 1E ), 5 expressing TRKB, BDNF, c-Kit, tryptase, and high affinity receptors for IgE (Fc«RI) and CD25 ( Figure 1G -H,J; supplemental Figure 1 ). Most SM animals followed an indolent course, and none of the animals became moribund or died before termination of the experiments. In contrast, leukemic mice survived ,6 months after transplantation. At the final analysis, most of the SM animals had normal blood counts; only 2 animals showed slight enlargement of spleen. There was no evidence of classical mast cell leukemia 6 or other hematological neoplasm in animals with SM. Moreover, no mutations in the c-Kit gene were detectable in any of the analyzed SM mice with high mast cell burden (n 5 4). In contrast to TRKB/ BDNF, no animals with TRKB alone, BDNF alone, or tCD34 showed mastocytosis or other hematological malignancies (supplemental Figure 2 ) except 1 TRKB mouse, which had slightly increased numbers of mastocytes (not fulfilling the criteria for SM) (supplemental Figure 3) , probably due to mild activation of TRKB by its overexpression. In historic controls of .60 animals transplanted in a similar setting with different genes, eg, EGFP, tCD34, dLNGFR, and SV40 LT, no animals demonstrated SM. These data strongly suggest that activation of TRKB by BDNF (autocrine or paracrine; Figure 1G ) is important to promote mastocytosis. Interestingly, TRKB activation in our model efficiently induced SM (incidence: 12/17 5 71%), whereas KIT D816V transgenic mice demonstrated a lower incidence of SM (8/28 5 29%). 7 Furthermore, retroviralmediated expression of KIT D816V even failed to induce SM in transplanted animals. 8 Interestingly, in contrast to transplantation with primary hematopoietic stem/ progenitor cells, C3H/HeJ animals (n 5 5 in 2 independent experiments, including the recently published experiment 4 ) transplanted with TRKB and BDNF modified 32D cells (murine myeloid progenitors) developed only myeloid leukemia with no sign of increased mastocyte numbers. The fact that mastocytosis is induced only when TRKB is activated in hematopoietic stem/ progenitor cells strongly supports the accepted view that mast cells are derived from hematopoietic stem cells. 9 In summary, we provide the first direct evidence for induction of mastocytosis by activation of TRKB in hematopoietic stem/ progenitor cells in vivo. Our data strongly support the findings by Peng et al 1 and their hypothesis and indicate an important role of TRKB in the pathogenesis of mastocytosis.
